Live Markets
Wednesday, July 29, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets · Healthcare

Avenue Therapeutics, Inc. (ATXI)

OID · Biotechnology

$0.30+0.05 (+20.00%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
$988,490
P/E (TTM)
EPS
$-0.54
Div Yield
52W Range
$0.15–$0.97
Beta
-0.17

Company overview

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include ATX-04, a small molecule therapy for the treatment of Pompe disease; and intravenous tramadol, a schedule IV opioid to treat post-operative acute pain. The company was incorporated in 2015 and is headquartered in Bay Harbor Islands, Florida.

1 employeesavenuetx.com

Peers in Healthcare

Avenue Therapeutics, Inc. has no peer companies in this window.

Recent press releases

Avenue Therapeutics, Inc. has not issued a press release in this window.

SEC filings

All filings →

Avenue Therapeutics, Inc. has not filed an SEC document in this window.

Avenue Therapeutics, Inc. has no reported insider trades in the last 90 days.

Institutional holders

All holders →
As of 2024-12-31 · prior 2024-09-30
140,000 sh● NEW
41,089 sh● NEW
7,920 sh+28.9%
500 sh-10.9%
2 sh+100.0%

People at Avenue Therapeutics, Inc.

All people →

Quarterly financials

Full financials →
Revenue trend
03/25
NI -$1.9M
06/25
$1.4M
NI $335.0K
09/25
NI -$683.0K
RevenueNI = Net Income
EPS trend (diluted)
Latest: $-0.21
Prior: $0.00
Revenue sparkline